Photo from Agenus/LinkedIn
Sep 21, 2023, 17:50
TIGIT bispecific program is advancing in clinical trials for non-small cell lung and gastric cancers. – Agenus
Agenus shared on LinkedIn:
“Our partner, Bristol Myers Squibb, unveiled exciting updates at their recent R&D Day about their TIGIT bispecific program, which was licensed from Agenus in 2021. This is a differentiated bispecific antibody that potentially enhances the quality and magnitude of immune responses by targeting TIGIT and CD96. The program is advancing in clinical trials for non-small cell lung and gastric cancers. We are encouraged by these latest developments and look forward to future updates regarding this program.”
Source: Agenus/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 17:57
Nov 14, 2024, 17:46
Nov 14, 2024, 17:46
Nov 14, 2024, 17:42
Nov 14, 2024, 17:14